| 0.327 -0.008 (-2.39%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.47 | 1-year : | 0.56 |
| Resists | First : | 0.4 | Second : | 0.47 |
| Pivot price | 0.36  |
|||
| Supports | First : | 0.28 | Second : | 0.23 |
| MAs | MA(5) : | 0.33  |
MA(20) : | 0.34 |
| MA(100) : | 0.57 |
MA(250) : | 1.01 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.4 |
D(3) : | 22.7 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 2.19 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ COEP ] has closed above bottom band by 21.9%. Bollinger Bands are 45.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.35 - 0.35 | 0.35 - 0.35 |
| Low: | 0.32 - 0.32 | 0.32 - 0.32 |
| Close: | 0.32 - 0.33 | 0.33 - 0.33 |
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Wed, 24 Apr 2024
Dave Mehalick from Coeptis Therapeutics to Host InvestorTalk (04.25.2024) - InvestorNews - InvestorNews Inc.
Tue, 02 Apr 2024
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 ... - PR Newswire
Mon, 01 Apr 2024
COEP Stock Earnings: Coeptis Therapeutics Beats EPS for Q4 2023 - MSN
Mon, 01 Apr 2024
COEP Stock Earnings: Coeptis Therapeutics Beats EPS for Q4 2023 - InvestorPlace
Mon, 04 Mar 2024
Coeptis Therapeutics' Dave Mehalick on the disruptive potential of SNAP-CAR technology for autoimmune diseases ... - InvestorNews Inc.
Mon, 26 Feb 2024
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for ... - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
PNK
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 36 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 32.5 (%) |
| Held by Institutions | 13.1 (%) |
| Shares Short | 108 (K) |
| Shares Short P.Month | 166 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -168.1 % |
| Return on Equity (ttm) | -485.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.4 |
| PEG Ratio | 0 |
| Price to Book value | 2.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|